Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$3.87B+227.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jon Rousseau
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 23,500
- Beta
- 1.85
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 4.66
Financials
Revenue
$3.87B+227.3%Net Income
$86.69MEBITDA
$186.02M+391.6%Free Cash Flow
$14.88M-65.2%EPS (diluted)
$0.39Shares Outstanding (diluted)
220.28M+28.7%Operating Expenses
$348.15MCash & Debt
$550.38MReturn of Capital
$60.00MRevenue by Segment (annual)
$4.80BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $12.91B | $190.67M | $0.94 |
| 2024 | $11.27B | $-18.06M | $-0.09 |
| 2023 | $8.83B | $-154.60M | $-0.90 |
| 2022 | $7.72B | $-53.91M | $-0.31 |
| 2021 | $6.70B | $49.80M | $0.29 |
| 2020 | $5.58B | $20.81M | $0.12 |
| 2019 | $4.53B | $-72.38M | $-0.42 |
| 2018 | $2.54B | $-7.62M | $-0.04 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.38
- Implied price
- $55.32
- Return from $60.25
- -1.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $27.50 — -54.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 28 | 34 | 40 | 46 | 52 |
|---|---|---|---|---|---|
| -2.0% | -16.9% | -13.6% | -10.8% | -8.3% | -6.0% |
| 3.0% | -12.7% | -9.2% | -6.2% | -3.6% | -1.2% |
| 8.0% | -8.5% | -4.8% | -1.7% | 1.1% | 3.6% |
| 13.0% | -4.2% | -0.4% | 2.9% | 5.8% | 8.4% |
| 18.0% | 0.0% | 4.0% | 7.4% | 10.5% | 13.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (21)
- Newsglobenewswire.com·5d ago·Neutral
BrightSpring Health Services, Inc. to Announce Third Quarter 2026 Financial Results on October 30, 2026 LOUISVILLE, Ky., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its third quarter 2026 financial results on Friday, October 30, 2026, prior to the Company's earnings conference call, which will be held at 8:30 a.m. ET on the same day.
View source ↗ - Newszacks.com·5d ago·Positive
BTSG Deploys AI Across Operations: Will It Improve Margins? BrightSpring Health Services is expanding AI and automation across its operations, with early margin gains and more benefits expected later in 2026 and 2027.
View source ↗ - Newszacks.com·6d ago·Neutral
BrightSpring vs. Option Care Health: Which Healthcare Stock Is Better? BrightSpring's faster growth, pharmacy and provider-service expansion, and improving margins contrast with OPCH's slower growth and chronic-therapy pressures.
View source ↗ - Newsmarketbeat.com·9d ago·Neutral
BrightSpring Health Targets Growth Through Specialty Pharmacy, M&A and AI BrightSpring Health Services NASDAQ: BTSG outlined its growth strategy across pharmacy and provider services at the Bernstein healthcare services conference, emphasizing specialty pharmacy expansion, home health acquisitions, technology investments and opportunities to integrate services for complex patients.
View source ↗ - Newszacks.com·10d ago·Positive
Will M&A Be the Next Growth Factor as BTSG's Cash Flow and Leverage Improve? BTSG's stronger cash flow and lower leverage could give it more flexibility to pursue acquisitions and support future growth.
View source ↗ - Newszacks.com·11d ago·Positive
Best Momentum Stocks to Buy for September 24th RDVT, BTSG and THC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 24th, 2026.
View source ↗ - Newszacks.com·13d ago·Positive
3 Momentum Anomaly Stocks to Buy as Markets Surge on AI Rally Centene, BrightSpring and Delek combine 52-week gains with short-term pullbacks, putting them in focus as momentum plays for volatile markets.
View source ↗ - Newszacks.com·19d ago·Positive
BTSG Faces $200M IRA Hit but Efficiency May Protect Profitability BTSG faces a $200M 2026 IRA revenue headwind in Home Pharmacy, but efficiency gains and technology are helping protect profitability.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
BrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript BrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·24d ago·Positive
BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell? BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.
View source ↗ - Newszacks.com·25d ago·Neutral
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue? BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.
View source ↗ - Newsseekingalpha.com·26d ago·Neutral
BrightSpring Health Services: 44% Ebitda Growth Is Hard To Ignore BrightSpring Health Services is rated buy, driven by rapid profitability growth, expanding Provider Services, and reduced financial leverage. In Q2, revenue grew 23% and adjusted EBITDA surged 44%, with management raising 2026 guidance for both revenue and EBITDA. BTSG's premium 34.38x FY1 P/E is justified by strong EBITDA growth and a forward PEG of 0.73x, with multiples declining to 22.19x by FY3.
View source ↗ - Newszacks.com·31d ago·Neutral
Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth? BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.
View source ↗ - Newsdefenseworld.net·34d ago·Positive
BrightSpring Health Services, Inc. (NASDAQ:BTSG) Receives Consensus Rating of “Buy” from Brokerages Shares of BrightSpring Health Services, Inc. (NASDAQ: BTSG - Get Free Report) have been assigned an average recommendation of "Buy" from the twenty research firms that are covering the company, Marketbeat.com reports. Eighteen equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The
View source ↗ - Newszacks.com·41d ago·Positive
New Strong Buy Stocks for August 26th BTSG, OPHC, HRTG, UMC and MTG have been added to the Zacks Rank #1 (Strong Buy) List on August 26th, 2026.
View source ↗ - Newszacks.com·42d ago·Positive
Sandisk & 2 Profitable Stocks to Buy Now for Explosive Upside Sandisk, Celestica and BrightSpring rank among profitable stocks, with strong net income ratios and earnings growth supporting upside.
View source ↗ - Newszacks.com·42d ago·Negative
3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage CareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.
View source ↗ - Newsbenzinga.com·45d ago·Neutral
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
View source ↗ - Newszacks.com·45d ago·Neutral
BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue? BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.
View source ↗ - Newszacks.com·54d ago·Neutral
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.
View source ↗ - Newsseekingalpha.com·56d ago·Neutral
BrightSpring Health Services: A Great Business, But I'm Waiting For A Better Entry BrightSpring Health Services (BTSG) has delivered 22% revenue CAGR over five years, with strong segment growth and a compelling integrated care platform. BTSG's Onco360 specialty pharmacy and high-margin Provider Solutions drive recurring revenue, benefiting from secular demand and insurer preference for integrated services. Valuation suggests limited upside despite strong growth prospects.
View source ↗
Earnings
Fri, Oct 30(in 3 weeks)
Consensus estimate $0.47 per share
Typical surprise +15.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$0.45 vs $0.40beat
- Fri, May 1$0.39 vs $0.29beat
- Fri, Feb 27$0.33 vs $0.34miss
- Fri, Oct 31$0.30 vs $0.26beat
- Fri, Aug 1$0.22 vs $0.19beat
- Fri, May 2$0.19 vs $0.08beat
Estimates and results for BTSG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BTSG officers and directors.
- Bought
- —
- Sold
- $4.9bn
0 trades
21 trades
- Greenwell Scott A.sold
- Kkr Group Partnership L.p.sold
- Kkr Phoenix Aggregator L.p.sold
- Rousseau Jon Bsold
- Rousseau Jon Bsold
- Nalley Lisa Asold
- Phipps Jennifer Asold
- Nalley Lisa Asold
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BTSG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.